Replimune Group (NASDAQ:REPL) Given “Sell” Rating at HC Wainwright

HC Wainwright reiterated their sell rating on shares of Replimune Group (NASDAQ:REPL) in a research report released on Monday, MarketBeat Ratings reports.

Several other equities analysts have also issued reports on REPL. Wedbush lifted their target price on Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. Piper Sandler lowered Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Six analysts have rated the stock with a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $4.63.

Replimune Group Stock Performance

REPL stock opened at $1.70 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The business has a 50-day moving average price of $7.41 and a 200 day moving average price of $7.94. The company has a market capitalization of $140.37 million, a P/E ratio of -0.49 and a beta of 0.74. Replimune Group has a 1-year low of $1.50 and a 1-year high of $13.24.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.08. As a group, equities research analysts forecast that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total value of $52,065.00. Following the transaction, the insider owned 151,588 shares in the company, valued at $1,214,219.88. The trade was a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently modified their holdings of REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Replimune Group by 17.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after acquiring an additional 6,653 shares during the last quarter. Millennium Management LLC grew its stake in shares of Replimune Group by 2.8% during the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after acquiring an additional 33,574 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after acquiring an additional 119,145 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after acquiring an additional 6,616 shares during the last quarter. Finally, Sei Investments Co. grew its stake in shares of Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock worth $283,000 after acquiring an additional 18,263 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Key Stories Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Company response — Replimune’s executive chairman publicly called the FDA decision “unfair” and discussed next steps in a TV interview; management tone suggests they will contest or seek clarification with the agency. Replimune co-founder calls FDA rejection ‘unfair’
• Neutral Sentiment: Market mechanics — Trading on REPL was temporarily halted (LULD pause) during the sell-off as the market digested the CRL. (Intraday regulatory pause)
• Neutral Sentiment: Industry analysis — A PharmTech piece reviews lessons from the RP1 CRL for other developers; useful context but does not change Replimune’s immediate financials. What Pharma Developers Can Learn From RP1’s Rejection
• Negative Sentiment: Regulatory setback — The FDA issued a CRL for RP1’s Biologics License Application for advanced melanoma, delaying approval and forcing Replimune to address agency deficiencies before any potential approval. FDA Issues CRL to Replimune for RP1 BLA
• Negative Sentiment: Second CRL / program risk — Coverage notes this is a second CRL for RP1, increasing uncertainty about the regulatory path and timing for any approval or label; that uncertainty undermines near-term revenue and valuation expectations. Replimune Gets Second FDA CRL
• Negative Sentiment: Market reaction — Major outlets report REPL plunged to an all-time low on the news, with heavy trading and a dramatic drop in market value. Street sours on Replimune
• Negative Sentiment: Cost actions — Reports indicate Replimune is planning layoffs after the FDA decision, signaling management expects reduced near-term operating activity and is cutting burn. Replimune plans layoffs after FDA rejects cancer therapy
• Negative Sentiment: Analyst reaction — Multiple firms cut ratings and slashed price targets (downgrades and lower PTs from Jefferies, BMO, Wedbush, Leerink, JPMorgan, HC Wainwright, Piper and others), reflecting reduced probability of near-term upside. FDA Rejection Sparks Questions On Replimune Drug Approval Path

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.